Is It Safe to Take an SSRI During Pregnancy? What Informed Consent Should Cover

For most people, staying on an SSRI during pregnancy is the lower-risk choice, and the published data support that. First-trimester sertraline exposure shows no measurable increase in major birth defects above the 2 to 4 percent background rate that every pregnancy carries, according to the FDA-approved Zoloft label. The real gap is not the evidence, it is the conversation. Proper informed consent for SSRIs in pregnancy means hearing the absolute numbers on both sides of the decision, including the risk of relapse if the medication stops, and then choosing for yourself. Most people get a 40 second reassurance or a 40 second warning instead. This article gives you the numbers, the sources, and the questions that force a real discussion.

What informed consent for SSRIs in pregnancy actually requires

Informed consent is a legal and ethical standard requiring that you receive the known benefits, the known risks, the alternatives, and the consequences of doing nothing, in language you understand, with enough time to decide without pressure. It is not a signature on a form and it is not a reassuring sentence.

For SSRIs in pregnancy, a consent conversation that meets that standard covers 4 things. It covers what the medication does for your specific condition and how well it has worked for you. It covers the fetal and neonatal outcomes that have actually been studied, in absolute numbers rather than relative risk. It covers what happens to your mental health if the medication is reduced or stopped, which is a risk in its own right. And it covers the alternatives, including therapy, dose adjustment, and continuing exactly as you are.

The failure mode runs in both directions. Some prescribers deliver a flat "it's fine, everyone stays on it" that never mentions neonatal adaptation signs, so the parent is blindsided in the delivery room. Others deliver a flat "you need to come off this" that never mentions relapse rates, so the parent stops abruptly at 6 weeks pregnant and is severely unwell by the second trimester. Both are consent failures, and both are common.

The UK's NICE guideline on antenatal and postnatal mental health (CG192) is explicit that decisions about psychotropic medication in pregnancy should be shared, individualized, and revisited, not issued as instructions. The site's deprescribing curriculum, written for clinicians and open to anyone, covers the patient communication side of these decisions.

Bottom line: informed consent for SSRIs in pregnancy means absolute numbers on both the risk of taking and the risk of stopping, not reassurance and not a warning.

What the research shows about SSRI exposure during pregnancy

The outcomes that get studied most are birth defects, persistent pulmonary hypertension of the newborn, neonatal adaptation signs, postpartum hemorrhage, and neurodevelopment. Here is what the primary literature actually found.

Outcome studied	What the research found	What this means in practice
Major birth defects	No significant increase in cardiac defects after adjusting for maternal depression, RR 1.06 (95% CI 0.93 to 1.22), in Huybrechts et al., New England Journal of Medicine 2014	Earlier alarming figures largely reflected the illness, not the drug
Persistent pulmonary hypertension (PPHN)	31.5 per 10,000 exposed versus 20.8 per 10,000 unexposed, weakening to adjusted OR 1.10 (95% CI 0.94 to 1.29) in Huybrechts et al., JAMA 2015	A real but very small absolute difference, roughly 1 additional case per 1,000
Neonatal adaptation signs	Reported in up to 30 percent of neonates exposed in late pregnancy, per Moses-Kolko et al., JAMA 2005	Common, usually mild, usually resolves within 2 weeks, but you should be warned in advance
Postpartum hemorrhage	Less than a 2-fold increase with exposure in the month before delivery, per the FDA-approved sertraline labeling	Worth telling your obstetric team so they plan for it
Autism spectrum disorder	Association fell to non-significance after propensity matching and sibling comparison in Brown et al., JAMA 2017	The signal tracks maternal illness and family factors more than exposure

Two patterns run through all of it. First, every unadjusted number looks worse than the adjusted one, because depression itself affects pregnancy outcomes and the people taking SSRIs are the people who have depression. Second, the absolute risks are small even where a real association survives adjustment.

Bottom line: the studied fetal risks of SSRI exposure in pregnancy are small in absolute terms, and the largest apparent risks shrink or vanish once maternal illness is accounted for.

The risk that consent conversations usually skip: stopping an SSRI in pregnancy

The most consistently omitted number in these conversations is the relapse rate. A prospective study of 201 pregnant women with a history of major depression who were well at conception found that 68 percent of those who discontinued their antidepressant relapsed during pregnancy, compared with 26 percent of those who stayed on it (Cohen et al., JAMA 2006).

That study has real limitations and honest consent includes them. The sample came from specialist referral clinics, so these were people with more recurrent and more severe depression than average. Discontinuation was not randomized, meaning the people who stopped may have differed from the people who continued in ways the analysis could not capture. Most of the discontinuations were abrupt or fast rather than gradual.

Even with those caveats, the direction is not in dispute, and untreated depression in pregnancy is not a neutral outcome. It is associated with poorer prenatal care, worse nutrition, higher rates of substance use, and elevated risk of postpartum depression. A decision framework that counts only fetal medication exposure and assigns zero weight to maternal illness is not a balanced framework.

The third limitation matters most for anyone reading this who does want to reduce or stop. Stopping fast and tapering slowly are different interventions with different outcomes, and the relapse figures above mostly describe the fast version. Withdrawal symptoms from a rapid reduction are also easy to misread as relapse, which pushes people back onto medication they might have come off successfully at a slower rate.

Bottom line: stopping an SSRI carries its own measurable risk, roughly 68 percent relapse in one prospective cohort of previously well women, and any consent conversation that leaves that number out is incomplete.

I just found out I'm pregnant and I'm on Zoloft. Should I stop today?

No. Stopping Zoloft or any SSRI abruptly on a positive pregnancy test is the single most common harmful reaction to this news, and it is the one most likely to make things worse.

By the time a pregnancy test turns positive, exposure during the earliest weeks has already happened. Organ formation begins around week 3. Stopping on the day of the test does not undo first-trimester exposure, and the exposure it does prevent is the exposure the research associates with the smallest risks. Meanwhile the abrupt stop creates two new problems immediately: withdrawal symptoms, which are worst after sudden cessation of short half-life drugs like Paxil and venlafaxine, and a sharply elevated chance of relapse during a pregnancy you now need to be well for.

What to do instead is get a real appointment within the next week or two and go in prepared. Bring your history, including what happened the last time you reduced or stopped, what dose you have been stable on and for how long, and what your symptoms looked like at their worst. That history is the single most useful input to the decision and almost nobody brings it.

If after a proper conversation you and your prescriber decide to reduce, the reduction should be gradual and proportional rather than sudden. Reductions of a fixed fraction of your current dose, getting smaller in absolute terms as the dose falls, are what the pharmacology supports (Horowitz and Taylor, Lancet Psychiatry 2019), and the taper planner shows you what that curve looks like for your medication. This is a decision to make with clinical support, not one to improvise in week 5.

Bottom line: do not stop an SSRI the day you find out you are pregnant, because the exposure has already happened and the abrupt stop adds withdrawal and relapse risk on top of it.

Questions to ask your prescriber before deciding about an SSRI in pregnancy

Consent conversations improve when you arrive with specific questions, because specific questions are harder to answer with reassurance.

Ask what the absolute risk is, not the relative risk. "Double the risk" means nothing until you know double of what. If the answer is 1 in 1,000 rising to 2 in 1,000, that is a very different decision from 1 in 10 rising to 2 in 10, and PPHN is squarely in the first category.

Ask whether the studies adjusted for depression itself. This one question separates the alarming headline numbers from the numbers that survive scrutiny, and a prescriber who cannot answer it is quoting a headline.

Ask what happens to the baby at delivery. Neonatal adaptation signs, including jitteriness, feeding difficulty, and irritability in the first days, are common enough that your delivery team should know about the exposure in advance. Being warned turns a frightening surprise into an expected, monitored, self-limiting event.

Ask what the plan is if symptoms return. A decision to reduce needs a defined point at which you stop reducing, and a defined response. Without one, every bad week becomes an argument.

Ask what the alternatives are and what the evidence is for each. Therapy, dose adjustment, and continuing unchanged are all real options, and continuing unchanged is a legitimate choice rather than a failure to act.

Finally, ask for the sources. Deprescribing.org publishes clinician-facing guidance on how these conversations are supposed to run, and you can read what clinicians are taught about tapering and patient communication here.

Bottom line: ask for absolute risks, whether studies adjusted for maternal illness, the delivery plan, and the stopping rule, because those 4 questions cannot be answered with reassurance.

My doctor says the risk is minimal and won't discuss it further. What can I do?

Being told the risk is minimal is not consent, even when the statement happens to be accurate. You are entitled to the numbers behind it and to have your own concerns addressed rather than managed.

Three things help. Put the request in writing through the patient portal, asking specifically for the absolute risk figures and the sources they are based on. A written question creates a record and tends to get a more careful answer than the same question at minute 12 of a 15 minute appointment.

Second, bring data instead of adjectives. "I feel worse" invites reassurance. A log showing which symptoms occurred on which days, at what severity, is clinical information, and it changes how the conversation goes. A symptom journal built for exactly this is free to use, and the same record is what makes any future reduction decision legible rather than guesswork.

Third, get a second opinion from someone who does this work regularly. Perinatal mental health specialists and clinicians experienced in deprescribing think about these decisions differently from a general practitioner seeing 30 patients a day, and our directory of deprescribing-informed clinicians is one place to start. Mad in America and the Inner Compass Initiative both publish patient-side accounts of what these conversations look like when they go well and when they do not.

If you are weighing a change and want the structure written down before the appointment, the tapering plan worksheet turns a vague intention into something a prescriber can respond to.

Bottom line: request the absolute numbers in writing, bring tracked symptom data rather than adjectives, and seek a perinatal or deprescribing-experienced second opinion if the conversation stays closed.

Frequently asked questions

Does taking an SSRI during pregnancy cause birth defects?

The large adjusted studies do not support that. Analysis of nearly 950,000 pregnancies found no significant increase in cardiac defects once maternal depression was accounted for, with a relative risk of 1.06 (95% CI 0.93 to 1.22) (Huybrechts et al., New England Journal of Medicine 2014). Every pregnancy carries a 2 to 4 percent background risk of major birth defects regardless of medication.

Is sertraline safer in pregnancy than other SSRIs?

Sertraline has the largest reassuring dataset, which is why it is frequently the first choice when someone is starting an antidepressant during pregnancy. That is a different question from whether you should switch. Switching medications mid-pregnancy exposes the baby to 2 drugs instead of 1 and risks destabilizing a person who is currently well, so an established, effective medication is usually kept. Lexapro and Prozac also have substantial pregnancy data.

What are neonatal adaptation signs and how long do they last?

Neonatal adaptation signs are transient symptoms in newborns exposed to SSRIs in late pregnancy, including jitteriness, irritability, feeding difficulty, and mild respiratory changes. They are reported in up to 30 percent of exposed neonates (Moses-Kolko et al., JAMA 2005), are usually mild, and typically resolve within about 2 weeks. Tell your delivery team about the exposure so they monitor for it.

Should I stop my SSRI before the third trimester to protect the baby?

That practice is common and the evidence for it is weak. Stopping late in pregnancy removes a small risk of neonatal adaptation signs while adding withdrawal symptoms and a relapse risk during the highest-risk window for postpartum depression. The NICE antenatal and postnatal mental health guideline does not recommend routine third-trimester discontinuation.

Can I refuse an SSRI in pregnancy if my doctor recommends one?

Yes. Informed consent includes the right to decline, and declining a recommended treatment does not end your care. Ask for the reasoning to be documented along with your decision, and agree on what would change the recommendation, so the choice is revisited deliberately rather than argued about at every appointment.

Where to go from here

The decision about an SSRI in pregnancy belongs to you, and it needs both sets of numbers to be made honestly. Fetal risks that survive adjustment are small in absolute terms. The risk of stopping abruptly is not small. Anyone handing you only one of those halves has not obtained your consent, they have obtained your agreement.

taper.community is a free peer forum and evidence library for people making decisions about psychiatric medication, built around hyperbolic tapering, informed consent, and reductions slow enough to tell withdrawal apart from relapse. If you want to prepare for the conversation, read through the deprescribing curriculum, then bring your own history in writing. If you want to hear from people who have been through this decision, the forums are open and free to join.

This article is for information only and is not medical advice. Decisions about psychiatric medication during pregnancy should be made with a qualified clinician who knows your history. Do not start, stop, or change a dose based on this article alone.